Filing Flows › Eton Pharmaceuticals (ETON) › Q3 2026 › vs Q2 2026
Eton Pharmaceuticals (ETON) Q3 2026 vs Q2 2026 (quarter over quarter)
Eton Pharmaceuticals's revenue rose $20.3M (+54%) from $37.6M in Q2 2026 to $57.9M in Q3 2026. Gross margin 76.5% against 67.6% (+8.9 pts).
Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 76.5% | 67.6% | +8.9 pts |
| Operating margin | 39.7% | 34.0% | +5.7 pts |
| Net margin | 60.9% | 30.8% | +30.1 pts |
| Free cash flow margin | 60.8% | 19.3% | +41.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $57.9M | $37.6M | $20.3M | +54% |
| Gross profit | $44.3M | $25.4M | $18.9M | +74% |
| Cost of revenue | $13.6M | $12.2M | $1.4M | +12% |
| Operating profit | $23.0M | $12.8M | $10.2M | +80% |
| Operating expenses | $21.3M | $12.6M | $8.7M | +69% |
| Pre-tax earnings | $22.4M | $11.7M | $10.6M | +91% |
| Other expense, net | $656K | $1.1M | −$420K | -39% |
| Research & development | $5.3M | $993K | $4.3M | +431% |
| General & admin | $16.0M | $11.6M | $4.4M | +38% |
| Income tax benefit | $12.9M | −$140K | $13.0M | — |
| Net earnings | $35.2M | $11.6M | $23.7M | +204% |
| Depreciation & amortization | $1.4M | $1.4M | $58K | +4% |
| Share-based compensation | $3.3M | $1.5M | $1.8M | +125% |
| Working capital & other | $4.8M | $7.2M | −$2.4M | -34% |
| Operating cash flow | $35.2M | $7.3M | $28.0M | +386% |
| Free cash flow (OCF − capex) | $35.2M | $7.3M | $28.0M | +385% |
| Capital expenditures | $13K | −$5K | $18K | — |
Questions
How much did Eton Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Eton Pharmaceuticals's revenue rose $20.3M (+54%) from $37.6M in Q2 2026 to $57.9M in Q3 2026. Gross margin 76.5% against 67.6% (+8.9 pts).